Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 9/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 9/20 | 0.36 |
| ▸ | KDR | P35968 | 8/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SORD | Q00796 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8142536 | 0.84 | TSHR (0.48) | KDM4EGAAHTTFGFR1FGFR2 | |
| SCHEMBL20309635 | 0.83 | KDM4E (0.37) | KDM4EGAAHTTFGFR1FGFR2 | |
| SCHEMBL16125136 | 0.83 | KDM4E (0.37) | KDM4EGAAHTTFGFR1FGFR2 | |
| SCHEMBL4215152 | 0.83 | SORD (0.42) | KDM4EGAAHTTFGFR1FGFR2 | |
| SCHEMBL14334526 | 0.81 | FGFR1 (0.40) | KDM4EGAAHTTFGFR1FGFR2 | |
| SCHEMBL2126277 | 0.81 | KDM4E (0.36) | KDM4EGAAHTTFGFR1FGFR2 | |
| SCHEMBL8142567 | 0.81 | SMN1; SMN2 (0.47) | KDM4EGAAHTTFGFR1FGFR2 | |
| SCHEMBL2125333 | 0.80 | FGFR1 (0.37) | KDM4EGAAFGFR1FGFR2FGFR4 | |
| SCHEMBL4068129 | 0.80 | KDM4E (0.36) | KDM4EGAAHTTFGFR1FGFR2 | |
| SCHEMBL13358949 | 0.79 | FGFR1 (0.37) | KDM4EGAAHTTFGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512858-B1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-08 | — | — | EP | disclosed |
| CN-109715634-B | Fused bicyclic inhibitors of MENIN-MLL interaction | 詹森药业有限公司 | 2022-09-27 | — | — | CN | disclosed |
| US-10975100-B2 | Fused bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-13 | — | — | US | disclosed |
| US-20200172556-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| US-10611778-B2 | Fused bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-07 | — | — | US | disclosed |
| US-20190218230-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | Janssen Pharmaceultica nv (BE) | 2019-07-18 | — | — | US | disclosed |
| EP-2855480-B1 | PTERIDINES AS FGFR INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2019-06-26 | — | — | EP | disclosed |
| US-10272087-B2 | Pteridines as FGFR inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2019-04-30 | — | — | US | disclosed |
| EP-2776436-B1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2019-03-13 | — | — | EP | disclosed |
| US-10039759-B2 | Quinolines as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2018-08-07 | — | — | US | disclosed |
| EP-2776435-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | Astex Therapeutics Limited (GB) | 2014-09-17 | — | — | EP | disclosed |
| US-20140072576-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8614323-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-24 | — | — | US | disclosed |
| EP-2657235-A1 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-30 | — | — | EP | disclosed |
| WO-2013061080-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| US-20120328627-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-12-27 | — | — | US | disclosed |
| US-8318931-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8293896-B2 | — | — | 2012-10-23 | — | — | US | disclosed |
| US-20090118279-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1942108-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218230-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, BMI1, MEN1 | KDM4E 542/4885GAA 4461/4885HTT 3089/4885 |
| US-20140072576-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR1, CXCR3 | KDM4E 4377/4885GAA 4348/4885HTT 2895/4885 |
| US-10611778-B2 | Fused bicyclic inhibitors of menin-MLL interaction | MLLT1, BMI1, MEN1 | KDM4E 542/4885GAA 4461/4885HTT 3089/4885 |
| US-10039759-B2 | Quinolines as FGFR kinase modulators | FGFR1, FGFR3, FGFR2 | KDM4E 1082/4885GAA 1098/4885HTT 1524/4885 |
| US-10272087-B2 | Pteridines as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | KDM4E 686/4885GAA 1262/4885HTT 2157/4885 |
| US-20200172556-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, BMI1, MEN1 | KDM4E 542/4885GAA 4461/4885HTT 3089/4885 |
| US-10975100-B2 | Fused bicyclic inhibitors of menin-MLL interaction | MLLT1, BMI1, MEN1 | KDM4E 542/4885GAA 4461/4885HTT 3089/4885 |
| US-20090118279-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | CXCR4, CXCR1, CXCR3 | KDM4E 3862/4885GAA 3207/4885HTT 2978/4885 |
| US-20120328627-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR1, CXCR3 | KDM4E 4377/4885GAA 4348/4885HTT 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.